Business
Accuray Announces First 100 Patient Treatment Regimens Completed in China Using the Tomo® C Radiation Treatment Delivery System, a CNNC-Accuray Joint Venture Product
MADISON, Wis., Jan. 23, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Shandong Cancer Hospital and Institute has achieved a
About this update from Accuray Incorporated
[{"type":"text","content":"MADISON, Wis., Jan. 23, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Shandong Cancer Hospital and Institute has achieved a milestone with the completion of treatment for 100 patients using the Tomo® C Radiation Treatment Delivery System, a product built in China through the CNNC-Accuray joint venture. Shandong Cancer Hospital and Institute was the first hospital in China to receive the new Tomo C System which has already demonstrated its value by expanding clinical capabilities and the opportunity to offer potentially curative treatment to more people diagnosed with cancer. This first cohort of Tomo C System treatments also represent a milestone for Accuray which is focused on addressing the broad needs of the underserved Chinese radiation therapy market.\n\n \n \n \n \n \n \n\n \nThe number of new cancer cases in China is anticipated to increase by almost 47 percent in the coming years with about 7.1 million people expected to be diagnosed in 2045, compared to an estimated 4.8 million people in 20221. The data reinforces the importance of advanced radiotherapy technology that enables the precise treatment of the full spectrum of cancer cases clinical teams see in their practice.\n\"We are proud to support the Shandong Cancer Hospital and Institute team as they enhance their cancer treatment options with the new Tomo C System. I am pleased that a wide range of cancer types were successfully treated among these 100 patients and that the fast speed of treatment is expected to meaningfully increase capacity - enabling them to treat more patients per day,\" said Suzanne Winter, president and CEO of Accuray.\nContinued Ms. Winter, \"The system was developed to enable more clinicians in China to offer fast, effective, personalized cancer care to their patients. Its introduction expands our product portfolio in this important region and reinforces our commitment to providing our customers with the tools they need to offer the best care possible to any patient they believe would benefit from radiotherapy.\"\nShandong Cancer Hospital and Institute, founded in 1958, is a top center for cancer care, research, and prevention in China. Serving over 400,000 patients annually, it offers advanced treatments and collaborates with global leaders such as MD Anderson Cancer Center in the United States. The hospital ...